In the last two decades, functional imaging methods such as positron (PET) and single photon emission computed tomography (SPECT) have emerged as valuable tools to study the dopaminergic synapse in vivo. Investigations of dopamine transporter (DAT) and dopamine D 2 receptor (D 2 R) binding have yielded evidence that various neurological and psychiatric conditions such as Parkinson's disease, [1] [2] [3] schizophrenia, 4 depression, 5, 6 attention-deficit/hyperactivity disorder, 7 and drug abuse 8 are related to dysfunctions of the dopaminergic system.
Disturbances of dopaminergic neurotransmission among other factors may be due to changes in concentrations of synaptic dopamine and/or availabilities of pre-and postsynaptic transporter or receptor binding sites. Numerous in vivo findings suggest an interrelation between synaptic neurotransmitter concentrations and densities of pre-and postsynaptic binding sites. So it was demonstrated in patients with Parkinson's disease that the degeneration of the nigostriatal pathway leads to a decrease of available dopamine, which in turn leads to a reduction of striatal DAT density 1 and compensatory upregulations of postsynaptic D 2 R binding sites in the early stage of disease. 2 In later stages, also postsynaptically, reductions of D 2 R binding become apparent. 3 Similarly, in vivo studies indicate both a decrease of DAT 5 and an increase of D 2 R binding in depressive patients. 6 A further example is the effect of synaptic dopamine on postsynaptic D 2 R binding upon challenge with psychostimulants such as methylphenidate: Volkow and collaborators 8 demonstrated that this substance blocks the presynaptic DAT with the resulting increase of synaptic dopamine leading to a reduction of free postsynaptic D 2 R.
During the last few years, high-resolution PET and SPECT cameras are increasingly employed for the study of transporter and receptor binding in small laboratory animals. Thereby, most investigators focus on rat models of neurodegenerative diseases such as Parkinson's and Huntington's disease, and assess either DAT or D 2 R binding in lesioned and control animals with either dedicated small animal PET (for a review see Nikolaus et al 9 ) or conventional clinical SPECT cameras equipped with highly resolving single-pinhole collimators. [10] [11] [12] In one study, both pre-and postsynaptic binding were assessed in the same animals showing a decrease of DAT together with an increase of D 2 R binding contingent on 6-hydroxydopamine-lesion of the nigrostriatal pathway. 13 So far, however, no in vivo investigations have been performed in rats on the relation between synaptic dopamine and pre-/postsynaptic radioligand binding in quantitative terms.
We recently demonstrated that the dedicated small animal camera 'TierSPECT' may be used to quantify DAT 14 and D 2 R binding (in press) in the rat brain using
as radioligands. These investigations were the first small animal imaging studies assessing FP-CIT and IBZM binding in competition with exogenous and/or endogenous ligands in rats. Baseline DAT and D 2 R concentrations were obtained by quantifying striatal FP-CIT ( Figure  1a ) and IBZM binding (Figure 1d) , respectively, according to the method of Laruelle and collaborators. 15 In subsequent measurements, FP-CIT and IBZM binding were assessed after pharmacological blockade of DAT and D 2 R with methylphenidate (3 mg/kg, 10 mg/kg) and haloperidol (1 mg/kg), respectively. As methylphenidate binds to the DAT, the number of available presynaptic binding sites is reduced. As a consequence, with the doses of 3 and 10 mg/kg, FP-CIT binding in the rat striatum is decreased by B50% (Figure 1b ) and B80% (data not shown), respectively. Likewise, haloperidol competes with IBZM for the D 2 R binding sites leading to a B60% reduction of striatal IBZM binding (Figure 1d ). In the last experiment, the variation of free dopamine in the synaptic cleft was assessed by measuring IBZM binding to the D 2 R after challenge with methylphenidate (10 mg/kg). As methylphenidate increases dopamine concentrations in the synaptic cleft, due to competition with endogenous dopamine for D 2 R binding sites IBZM binding is reduced by B40% (Figure 1e) . Thus, decreases of IBZM binding relative to baseline provide estimations for increases of synaptic dopamine concentrations.
This series of experiments shows that multiple in vivo investigations of transporter and/or receptor binding are feasible with small animal SPECT. This approach provides insights into the pre-and/or postsynaptic mechanisms of dopaminergic neurons and thus holds promise for in vivo investigations on interrelations between transporter and/or receptor binding and varying levels of synaptic dopamine. This especially pertains to animal models of the attention-deficit/hyperactivity disorder, which is characterized by a dysregulation of synaptic dopamine. Moreover, in animal models of Parkinson's and Huntington's disease, longitudinal investigations of processes related to the depletion and recovery of endogenous dopamine may become feasible. This also holds for the study of compensatory mechanisms following brain lesions such as the development of receptor supersensitivity. Even more importantly, this research tool may be employed in future studies in order to explore interrelations between different neurotransmitter systems. This pertains to acetylcholine, glutamate, g-aminobutyric acid, adenosine and serotonin, which play major parts in the integration of striatal functions and are hypothesized to be related to the pathophysiology of disorders such as Parkinson's disease, schizophrenia, epilepsy, and drug abuse.
Taken together, this novel approach to perform multiple imaging studies of pre-and/or postsynaptic radioligand binding in the same rat may not only prove beneficial for better understanding synaptic changes related to the pathophysiology of human diseases but also for the development of novel diagnostic parameters and therapeutic strategies. 
